1
|
Nakamura M, Shimada K, Nakase H, et al:
Clinicopathological diagnosis of gliomas by genotype analysis.
Brain Nerve. 61:773–780. 2009.(In Japanese).
|
2
|
Mladkova N and Chakravarti A: Molecular
profiling in glioblastoma: prelude to personalized treatment. Curr
Oncol Rep. 11:53–61. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Huang H, Mahler-Araujo BM, Sankila A, et
al: APC mutations in sporadic medulloblastomas. Am J Pathol.
156:433–437. 2000. View Article : Google Scholar
|
4
|
Gilbertson RJ: Medulloblastoma: signalling
a change in treatment. Lancet Oncol. 5:209–218. 2004. View Article : Google Scholar : PubMed/NCBI
|
5
|
Misaki K, Marukawa K, Hayashi Y, et al:
Correlation of gamma-catenin expression with good prognosis in
medulloblastomas. J Neurosurg. 102:197–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ellison DW, Onilude OE, Lindsey JC, et al:
beta-Catenin status predicts a favorable outcome in childhood
medulloblastoma: the United Kingdom Children’s Cancer Study Group
Brain Tumour Committee. J Clin Oncol. 23:7951–7957. 2005.PubMed/NCBI
|
7
|
Oikonomou E, Barreto DC, Soares B, et al:
Beta-catenin mutations in craniopharyngiomas and pituitary
adenomas. J Neurooncol. 73:205–209. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Sekine S, Shibata T and Kokubu A:
Craniopharyngiomas of adamantinomatous type harbor beta-catenin
gene mutations. Am J Pathol. 161:1997–2001. 2002. View Article : Google Scholar : PubMed/NCBI
|
9
|
Gonzalez S, Pisano DG and Serrano M:
Mechanistic principles of chromatin remodeling guided by siRNAs and
miRNAs. Cell Cycle. 7:2601–2608. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Novakova J, Slaby O, Vyzula R, et al:
MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys
Res Commun. 386:1–5. 2009. View Article : Google Scholar
|
12
|
Si ML, Zhu S, Wu H, et al: miR-21-mediated
tumor growth. Oncogene. 26:2799–2803. 2007. View Article : Google Scholar : PubMed/NCBI
|
13
|
Tong AW and Nemunaitis J: Modulation of
miRNA activity in human cancer: a new paradigm for cancer gene
therapy? Cancer Gene Ther. 15:341–355. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kefas B, Godlewski J, Comeau L, et al:
microRNA-7 inhibits the epidermal growth factor receptor and the
Akt pathway and is down-regulated in glioblastoma. Cancer Res.
68:3566–3572. 2008. View Article : Google Scholar : PubMed/NCBI
|
15
|
Yang H: Nanoparticle-mediated
brain-specific drug delivery, imaging, and diagnosis. Pharm Res.
27:1759–1771. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Tomalia DA: A new class of polymers:
starburst-denfritic macromolecules. Polym J. 17:117–132. 1985.
View Article : Google Scholar
|
17
|
Malik N, Wiwattanapatapee R, Klopsch R, et
al: Dendrimers: relationship between structure and biocompatibility
in vitro, and preliminary studies on the biodistribution of
125I-labelled polyamidoamine dendrimers in vivo. J Control Release.
65:133–148. 2000.PubMed/NCBI
|
18
|
Huang S, Fu L, Zhang X, et al: Syntheses
of polyamidoamine dendrimers starting from a hexadimensional core
and application in gene transfer. Science in China Series B:
Chemistry. 46:271–279. 2003. View
Article : Google Scholar
|
19
|
Tang MX, Redemann CT and Szoka FC Jr: In
vitro gene delivery by degraded polyamidoamine dendrimers.
Bioconjug Chem. 7:703–714. 1996. View Article : Google Scholar : PubMed/NCBI
|
20
|
Luo D, Haverstick K, Belcheva N, et al:
Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible,
high-efficiency DNA delivery. Macromolecules. 35:3456–3462. 2002.
View Article : Google Scholar
|
21
|
Belda-Iniesta C, de Castro Carpeño J,
Sereno M, et al: Epidermal growth factor receptor and glioblastoma
multiforme: molecular basis for a new approach. Clin Transl Oncol.
10:73–77. 2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Loew S, Schmidt U, Unterberg A, et al: The
epidermal growth factor receptor as a therapeutic target in
glioblastoma multiforme and other malignant neoplasms. Anticancer
Agents Med Chem. 9:703–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zi X, Guo Y, Simoneau AR, et al:
Expression of Frzb/secreted Frizzled-related protein 3, a secreted
Wnt antagonist, in human androgen-independent prostate cancer PC-3
cells suppresses tumor growth and cellular invasiveness. Cancer
Res. 65:9762–9770. 2005. View Article : Google Scholar
|